Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation
Francesca Ratti,Rebecca Marino,Pim B Olthof,Johann Pratschke,Joris I Erdmann,Ulf P Neumann,Raj Prasad,William R Jarnagin,Andreas A Schnitzbauer,Matteo Cescon,Alfredo Guglielmi,Hauke Lang,Silvio Nadalin,Baki Topal,Shishir K Maithel,Frederik J H Hoogwater,Ruslan Alikhanov,Roberto Troisi,Ernesto Sparrelid,Keith J Roberts,Massimo Malagò,Jeroen Hagendoorn,Hassan Z Malik,Steven W M Olde Damink,Geert Kazemier,Erik Schadde,Ramon Charco,Philip R de Reuver,Bas Groot Koerkamp,Luca Aldrighetti,Perihilar Cholangiocarcinoma Collaboration Group,Fabian Bartsch,Wolf Bechstein,Jan Bednarsch,Christian Benzing,Stefan Buettner,Ivan Capobianco,Michael D'Angelica,Marieke T de Boer,Elise de Savornin Lohman,Maxime Dewulf,Mikhail Efanov,Lotte C Franken,Joachim Geers,Mariano Giglio,Stefan Gilg,Concepcion Gomez,Abdul Hakeem,Jan Heil,Frederik Hoogwater,Jan Jn Ijzermans,Hannes Jansson,Peter Kingham,Peter Lodge,Quintus Molenaar,Trong Anh Nguyen,Elizabeth Pando Rau,Martin Quinn,Matteo Ravaioli,Jens Rolinger,Andrea Ruzzenente,Moritz Schmelzle,Matteo Serenari,Thomas van Gulik,Stijn van Laarhoven,Lynn E van Nooijen,Jeroen LA van Vugt,Barbara Zonderhuis
DOI: https://doi.org/10.1097/HEP.0000000000000554
IF: 17.298
2024-02-01
Hepatology
Abstract:Background: While resection remains the only curative option for perihilar cholangiocarcinoma, it is well known that such surgery is associated with a high risk of morbidity and mortality. Nevertheless, beyond facing life-threatening complications, patients may also develop early disease recurrence, defining a "futile" outcome in perihilar cholangiocarcinoma surgery. The aim of this study is to predict the high-risk category (futile group) where surgical benefits are reversed and alternative treatments may be considered. Methods: The study cohort included prospectively maintained data from 27 Western tertiary referral centers: the population was divided into a development and a validation cohort. The Framingham Heart Study methodology was used to develop a preoperative scoring system predicting the "futile" outcome. Results: A total of 2271 cases were analyzed: among them, 309 were classified within the "futile group" (13.6%). American Society of Anesthesiology (ASA) score ≥ 3 (OR 1.60; p = 0.005), bilirubin at diagnosis ≥50 mmol/L (OR 1.50; p = 0.025), Ca 19-9 ≥ 100 U/mL (OR 1.73; p = 0.013), preoperative cholangitis (OR 1.75; p = 0.002), portal vein involvement (OR 1.61; p = 0.020), tumor diameter ≥3 cm (OR 1.76; p < 0.001), and left-sided resection (OR 2.00; p < 0.001) were identified as independent predictors of futility. The point system developed, defined three (ie, low, intermediate, and high) risk classes, which showed good accuracy (AUC 0.755) when tested on the validation cohort. Conclusions: The possibility to accurately estimate, through a point system, the risk of severe postoperative morbidity and early recurrence, could be helpful in defining the best management strategy (surgery vs. nonsurgical treatments) according to preoperative features.